Active Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 

血管内皮生长因子受体2(VEGFR2)活性蛋白

[PROPERTIES]

Source: Eukaryotic expression. Host: 293F cell

Residues: Ala20~Glu764

Tags: N-terminal His-tag

Purity: >98%

Endotoxin Level: <1.0EU per 1μg (determined by the LAL method). Buffer Formulation: 10mM PBS, pH7.6, containing 5% trehalose. Applications: Cell culture; Activity Assays. (May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.5

Predicted Molecular Mass: 84.9kDa

Accurate Molecular Mass: 90kDa as determined by SDS-PAGE reducing conditions. Phenomenon explanation:

The possible reasons that the actual band size differs from the predicted are asfollows:

1. Splice variants: Alternative splicing may create different sized proteins from the same gene.
2. Relative charge: The composition of amino acids may affects the charge of the protein.
3. Post-translational modification: Phosphorylation, glycosylation, methylation etc.
4. Post-translation cleavage: Many proteins are synthesized as pro-proteins, and then cleaved togive the active form.

5. Polymerization of the target protein: Dimerization, multimerization etc

[USAGE]

Reconstitute in 10mM PBS (pH7.6) to a concentration of 0.1-1.0 mg/mL. Do notvortex

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8ºC for one month.

Aliquot and store at -80ºC for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss ratewas determined by accelerated thermal degradation test, that is, incubate theprotein at 37ºC for 48h, and no obvious degradation and precipitation wereobserved. The loss rate is less than 5% within the expiration date underappropriate storage condition.

[SEQUENCE]

[ ACTIVITY ] 

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) also known as kinaseinsert domain receptor acts as a cell-surface receptor for VEGFA, VEGFC andVEGFD. VEGFR2 functions as the primary mediator of vascular endothelialgrowth factor activation in endothelial cells. Regulation of VEGFR-2 expressionappears critical in mitogenesis, differentiation, and angiogenesis. To test the effecton inhibit the VEGF-dependent proliferation of endothelium cells, ECV-304 cellswere seeded into triplicate wells of 96-well plates at a density of 5,000 cells/welland allowed to attach, replaced with serum-free overnight, then the medium wasreplaced with 2% serum standard DMEM including 1μg/mL Vascular EndothelialGrowth Factor C (VEGFC) and various concentrations of recombinant humanVEGFR2. After incubated for 96h, cells were observed by inverted microscope andcell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL ofCCK-8 solution was added to each well of the plate, then the absorbance at450nm was measured using a microplate reader after incubating the plate for 1-4hours at 37℃. Proliferation of ECV-304 cells after incubation with VEGFR2 for 96hobserved by inverted microscope was shown in Figure 1. Cell viability wasassessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinantVEGFR2 for 96h. The result was shown in Figure 2. It was obvious that VEGFR2significantly inhibit cell viability of ECV-304

[IDENTIFICATION]

Figure 4. SDS-PAGE

Sample: Active recombinant VEGFR2, Human

[IMPORTANT NOTE]

The kit is designed for research use only, we will not be responsible for any issue if the kit wasused in clinical diagnostic or any other procedures.

本产品只适用于科研，不能用于临床诊断。严禁用于临床医疗及其他非科研用途！

以实际收货产品说明书为准，网站说明书仅供参考。